Pictet Asset Management
SPRY icon

Pictet Asset Management’s ARS Pharmaceuticals SPRY Stock Holding History

Pictet Asset Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83K Hold
10,362
– – ﹤0.01% 2107
2026
Q1 		$83.2K Hold
10,362
– – ﹤0.01% 2058
2025
Q4 		$121K Sell
10,362
-176,364
-94% -$1.72M ﹤0.01% 1999
2025
Q3 		$1.82M Sell
186,726
-48,115
-20% -$691K ﹤0.01% 894
2025
Q2 		$4.27M Buy
+234,841
New +$3.39M ﹤0.01% 801

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

Pictet Asset Management's SPRY Position: Q2 2026 in Review

Pictet Asset Management held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 10,362 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #2107.

Pictet Asset Management first reported a position in SPRY in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.27M in Q2 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Pictet Asset Management held 10,362 shares of ARS Pharmaceuticals worth $83K as of Q2 2026.
  • Pictet Asset Management left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Pictet Asset Management's portfolio in Q2 2026, its #2107 holding.
  • Pictet Asset Management first reported a position in ARS Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Pictet Asset Management's ARS Pharmaceuticals position peaked at $4.27M in Q2 2025.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.